SLC22A1 1222AG SLC22A1 1222AG	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLCO1B3 334TT SLCO1B3 334TT	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLCO1B3 334TG SLCO1B3 334TG	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLCO1B3 334T SLCO1B3 334T	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials Lab Med - 1 week
SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG SLC22A1 480CC + SLC22A1 1222AG + SLCO1B3 334TT + SLCO1B3 334TG	Chronic Myeloid Leukemia CML	YD312 Sensitive: C3 – Early Trials Lab Med - 1 week
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	dasatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myeloid Leukemia CML	omacetaxine mepesuccinate Sensitive: A1 - Approval
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval
ABL1 T315I ABL1 T315I	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval
Chr t(1;16)(q12;q11.2) Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia CML	ponatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myeloid Leukemia CML	busulfan Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myelomonocytic Leukemia CMML	azacitidine Sensitive: A1 - Approval
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	nilotinib Sensitive: A1 - Approval
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	bosutinib Sensitive: A1 - Approval
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	imatinib Sensitive: A1 - Approval
No biomarker No biomarker	Chronic Myelomonocytic Leukemia CMML	decitabine/cedazuridine Sensitive: A1 - Approval
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	bosutinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	nilotinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	dasatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Chronic Myeloid Leukemia CML	YD312 Sensitive: A2 - Guideline
BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Sensitive: A2 - Guideline
BCR-ABL1 V299L BCR-ABL1 V299L	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 T315A BCR-ABL1 T315A	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 F317I BCR-ABL1 F317I	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 F317V BCR-ABL1 F317V	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 F317C BCR-ABL1 F317C	Chronic Myeloid Leukemia CML	dasatinib Resistant: A2 - Guideline
BCR-ABL1 Y253H BCR-ABL1 Y253H	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 E255V BCR-ABL1 E255V	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 F359I BCR-ABL1 F359I	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline
BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	bosutinib Resistant: A2 - Guideline
BCR-ABL1 F317L BCR-ABL1 F317L	Chronic Myeloid Leukemia CML	nilotinib Sensitive: A2 - Guideline
BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline
BCR-ABL1 L248V BCR-ABL1 L248V	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	ABL001 Sensitive: B - Late Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	HQP1351 Sensitive: B - Late Trials
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	ABL001 Sensitive: B - Late Trials
BCR-ABL1 G250E BCR-ABL1 G250E	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 Q252H BCR-ABL1 Q252H	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 F359C BCR-ABL1 F359C	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 Y253H BCR-ABL1 Y253H	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E355G BCR-ABL1 E355G	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 L387M BCR-ABL1 L387M	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E459K BCR-ABL1 E459K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 D276G BCR-ABL1 D276G	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E279K BCR-ABL1 E279K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 H396R BCR-ABL1 H396R	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 F486S BCR-ABL1 F486S	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials
BCR-ABL1 fusion BCR-ABL1 fusion	Chronic Myeloid Leukemia CML	ponatinib Sensitive: C1 - Off-label
BRAF V600E BRAF V600E	Chronic Myeloid Leukemia CML	vemurafenib Sensitive: C1 - Off-label
RUNX1 mutation RUNX1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C2 – Inclusion Criteria
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	ABL001 Sensitive: C2 – Inclusion Criteria
CSF3R T618I CSF3R T618I	Chronic Myeloid Leukemia CML	ruxolitinib Sensitive: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	dasatinib + nilotinib Resistant: C3 – Early Trials
BCR-ABL1 T315I BCR-ABL1 T315I	Chronic Myeloid Leukemia CML	PF-114 Sensitive: C3 – Early Trials
CIP2A-H CIP2A-H	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
miR-146a expression miR-146a expression	Chronic Myeloid Leukemia CML	imatinib Sensitive: C3 – Early Trials
IDH1 mutation IDH1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials
NPM1 mutation NPM1 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + nilotinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + bosutinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + ponatinib Sensitive: C3 – Early Trials
BCR-ABL1 mutation BCR-ABL1 mutation	Chronic Myeloid Leukemia CML	venetoclax + dasatinib Sensitive: C3 – Early Trials
BCR-ABL1 Q252H BCR-ABL1 Q252H	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials
BCR-ABL1 M351T BCR-ABL1 M351T	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials
BCR-ABL1 L248V BCR-ABL1 L248V	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials
BCR-ABL1 F359V BCR-ABL1 F359V	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials
KRAS G12A KRAS G12A	Chronic Myeloid Leukemia CML	GT19077 Sensitive: C3 – Early Trials
G0S2 overexpression G0S2 overexpression	Chronic Myeloid Leukemia CML	YD312 Sensitive: C3 – Early Trials
DNMT3A deletion DNMT3A deletion	Chronic Myeloid Leukemia CML	EGFR inhibitor Resistant: C3 – Early Trials
ASXL1 deletion ASXL1 deletion	Chronic Myeloid Leukemia CML	Tyrosine kinase inhibitor Resistant: C3 – Early Trials
KDM4D mutation KDM4D mutation	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials
ASXL1 mutation ASXL1 mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials
ABL1 T315I ABL1 T315I	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 F317L ABL1 F317L	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 T315I + M351T + L387M ABL1 T315I + M351T + L387M	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 F359V ABL1 F359V	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 G250E ABL1 G250E	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 Y253H ABL1 Y253H	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 E255K ABL1 E255K	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 D276G ABL1 D276G	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials
ABL1 M351T ABL1 M351T	Chronic Myeloid Leukemia CML	dasatinib Resistant: C3 – Early Trials

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

Chronic Myeloid Leukemia

Associations(254)

Associations
(254)